BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Klingler A, Regensburger D, Tenkerian C, Britzen-Laurent N, Hartmann A, Stürzl M, Naschberger E. Species-, organ- and cell-type-dependent expression of SPARCL1 in human and mouse tissues. PLoS One 2020;15:e0233422. [PMID: 32437418 DOI: 10.1371/journal.pone.0233422] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Liu B, Xiang L, Ji J, Liu W, Chen Y, Xia M, Liu Y, Liu W, Zhu P, Jin Y, Han Y, Lu J, Li X, Zheng M, Lu Y. Sparcl1 promotes nonalcoholic steatohepatitis progression in mice through upregulation of CCL2. J Clin Invest 2021;131:e144801. [PMID: 34651580 DOI: 10.1172/JCI144801] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
2 Rodrigues RM, Guan Y, Gao B. Targeting adipose tissue to tackle NASH: SPARCL1 as an emerging player. J Clin Invest 2021;131:e153640. [PMID: 34651578 DOI: 10.1172/JCI153640] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
3 Stürzl M, Kunz M, Krug SM, Naschberger E. Angiocrine Regulation of Epithelial Barrier Integrity in Inflammatory Bowel Disease. Front Med (Lausanne) 2021;8:643607. [PMID: 34409045 DOI: 10.3389/fmed.2021.643607] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
4 Nuñez-delMoral A, Brocos-Mosquera I, Vialou V, Callado LF, Erdozain AM. Characterization of Hevin (SPARCL1) Immunoreactivity in Postmortem Human Brain Homogenates. Neuroscience 2021;467:91-109. [PMID: 34033869 DOI: 10.1016/j.neuroscience.2021.05.017] [Reference Citation Analysis]